ATE549028T1 - Stabile analoga von glp-1 - Google Patents

Stabile analoga von glp-1

Info

Publication number: ATE549028T1
Authority: AT; Austria
Prior art keywords: glp; stable analogues; analogues; stable; proteolysis
Prior art date: 2003-05-15

Application number

AT04752496T

Other languages

English (en)

Inventor

William Bachovchin

Hung-Sen Lai

David Sanford

Original Assignee

Tufts College

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-05-17

Publication date

2012-03-15

2004-05-17 Application filed by Tufts College filed Critical Tufts College

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE549028T1 publication Critical patent/ATE549028T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000017854 proteolysis Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Polymers & Plastics (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Food Science & Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Animal Husbandry (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)

AT04752496T 2003-05-15 2004-05-17 Stabile analoga von glp-1 ATE549028T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47141103P	2003-05-15	2003-05-15
PCT/US2004/015488 WO2004103390A2 (en)	2003-05-15	2004-05-17	Stable analogs of peptide and polypeptide therapeutics

Publications (1)

Publication Number	Publication Date
ATE549028T1 true ATE549028T1 (de)	2012-03-15

Family

ID=33476839

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752496T ATE549028T1 (de)	2003-05-15	2004-05-17	Stabile analoga von glp-1

Country Status (10)

Country	Link
US (4)	US7259234B2 (de)
EP (1)	EP1633384B1 (de)
JP (1)	JP4699374B2 (de)
CN (2)	CN1822851B (de)
AT (1)	ATE549028T1 (de)
AU (2)	AU2004240630B2 (de)
CA (1)	CA2525574C (de)
ES (1)	ES2383752T3 (de)
IL (2)	IL171854A (de)
WO (1)	WO2004103390A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050272652A1 (en) *	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2316470A3 (de)	2001-11-26	2011-08-24	Trustees Of Tufts College	Peptidomimetikuminhibitoren von post-Prolin-spaltenden Enzymen
WO2003045228A2 (en) *	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
GB0205693D0 (en) *	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
US7691967B2 (en) *	2002-04-30	2010-04-06	Trustees Of Tufts College	Smart pro-drugs of serine protease inhibitors
ATE549028T1 (de) *	2003-05-15	2012-03-15	Tufts College	Stabile analoga von glp-1
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
AU2005216970B2 (en) *	2004-02-23	2011-07-07	Trustees Of Tufts College	Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko)	2005-02-11	2007-12-06	아밀린 파마슈티칼스, 인크.	선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2007022123A2 (en) *	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
CA2622069A1 (en) *	2005-09-08	2007-03-15	Uutech Limited	Treatment of diabetes related obesity
US8318668B2 (en) *	2005-09-08	2012-11-27	Trustees Of Tufts College	Stabilized GLP-1 analogs
CA2623412A1 (en) *	2005-09-08	2007-03-15	Uutech Limited	Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2477286C2 (ru)	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
DK2118123T3 (en)	2007-01-31	2016-01-25	Dana Farber Cancer Inst Inc	Stabilized p53 peptides and uses thereof
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8592377B2 (en)	2007-03-28	2013-11-26	President And Fellows Of Harvard College	Stitched polypeptides
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
ES2509883T3 (es)	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
MX2010004298A (es)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
US20090178317A1 (en) *	2008-01-11	2009-07-16	Adams John E	Sign with waterproof pocket
EP2279011B1 (de)	2008-04-30	2017-10-25	Siemens Medical Solutions USA, Inc.	Auf substrat basierende pet-kontrastmittel
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
WO2010016940A2 (en) *	2008-08-07	2010-02-11	Ipsen Pharma S.A.S.	Analogues of glucose-dependent insulinotropic polypeptide
KR20110043687A (ko)	2008-08-07	2011-04-27	입센 파마 에스.에이.에스	포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
ES2574835T3 (es)	2008-08-07	2016-06-22	Ipsen Pharma S.A.S.	Análogos del polipéptido insulinotrópico dependiente de glucosa
US8299023B2 (en) *	2008-09-17	2012-10-30	Hoffmann-La Roche Inc.	Neuropeptide-2 receptor (Y-2R) agonists
PE20120332A1 (es)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (de)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Gip-rezeptor-aktive glucagon-verbindungen
EP2311486A1 (de) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
EP2560675A1 (de)	2010-04-20	2013-02-27	Novo Nordisk A/S	Lang wirksame gastrinderivate
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
ES2711526T3 (es)	2010-08-13	2019-05-06	Aileron Therapeutics Inc	Macrociclos peptidomiméticos
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
CN102675453B (zh) *	2011-03-09	2016-04-20	中肽生化有限公司	一种促肾上腺皮质激素的类似物及其制备方法和用途
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
PL2753334T3 (pl)	2011-08-30	2022-12-12	Trustees Of Tufts College	Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
TW201806968A (zh)	2011-10-18	2018-03-01	艾利倫治療公司	擬肽巨環化合物
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
BR112014020103A2 (pt)	2012-02-15	2018-10-09	Aileron Therapeutics, Inc.	macrociclos peptidomiméticos
EP2819688A4 (de)	2012-02-15	2015-10-28	Aileron Therapeutics Inc	Triazol- und thioethervernetzte peptidomimetische makrozyklen
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014071241A1 (en)	2012-11-01	2014-05-08	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
JP2017513875A (ja) *	2014-04-22	2017-06-01	ティーエックスピーファーマゲゼルシャフトミットベシュレンクテルハフツング	分枝状アミノ酸プローブを有するペプチド類似体
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104004059B (zh) *	2014-06-23	2016-03-30	周越	一种关于白介素-33抑制剂多肽及其应用
CN104004061B (zh) *	2014-06-23	2016-03-02	南通普悦生物医药有限公司	白介素-33抑制剂多肽及其应用
EP3197478A4 (de)	2014-09-24	2018-05-30	Aileron Therapeutics, Inc.	Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en)	2015-03-20	2016-09-29	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US11617832B2 (en) *	2016-08-17	2023-04-04	International Business Machines Corporation	Portal system-based bionic pancreas
EP3526242A1 (de)	2016-10-12	2019-08-21	University of Copenhagen	Duale peptidagonisten von gipr und glp2r
AU2018345601B2 (en)	2017-10-02	2025-05-15	Verra Therapeutics LLC	Methods and compositions for inhibiting ADAM10 biological activities
JP2021512596A (ja)	2018-01-31	2021-05-20	ヴェラセラピューティクスエルエルシー	Ａｄａｍ９生物活性を阻害するための方法および組成物
MX2020010505A (es)	2018-04-05	2021-01-15	Sun Pharmaceutical Ind Ltd	Analogos novedosos de glp-1.
CN108853147B (zh) *	2018-07-24	2021-12-24	苏州大学	一种缓释外泌体的多肽纳米纤维水凝胶及其制备方法与应用
CN109232747B (zh) *	2018-09-26	2019-06-11	哈尔滨工业大学	强啡肽a(1-8)与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
CN111265653B (zh) *	2020-02-09	2023-05-09	华中科技大学同济医学院附属协和医院	心房利钠肽在制备炎症性肠病治疗药物中的应用
CN116023444B (zh) *	2022-08-12	2023-08-01	重庆宸安生物制药有限公司	一种gip和glp-1双受体激动剂多肽化合物及其应用
CN117797325A (zh) *	2023-11-29	2024-04-02	浙江大学绍兴研究院	一种含类肽的抗菌涂层及其制备方法
CN119192324A (zh) *	2024-09-30	2024-12-27	华南理工大学	具有改善睡眠活性的Tyr-Pro-型酪蛋白肽及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5328899A (en)	1988-07-15	1994-07-12	The Salk Institute For Biological Studies	NPY peptide analogs
US5026685A (en)	1988-07-15	1991-06-25	The Salk Institute For Biological Studies	NPY peptide analogs
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
JPH0449298A (ja)	1990-06-19	1992-02-18	Univ New York State	新規なエンケファリン誘導体および鎮痛剤
CA2131315A1 (en)	1992-03-25	1993-09-30	Geert J. Ensing	Method of intraoperatively detecting and locating tumoral tissues
DK0678018T3 (da)	1993-01-06	2003-04-28	Kinerton Ltd	Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US6075009A (en)	1995-04-17	2000-06-13	East Carolina University	Neuropeptide Y analogues, compositions and methods of lowering blood pressure
US6410701B1 (en)	1995-05-05	2002-06-25	Human Genome Sciences, Inc.	Human neuropeptide receptor
US5766620A (en)	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
EP1049486A4 (de)	1997-12-05	2006-01-04	Lilly Co Eli	Glp-1 formulierungen
EP1054594B1 (de)	1998-02-13	2007-07-04	Amylin Pharmaceuticals, Inc.	Inotropische und diuretische effekte von exendin und glp-1
WO1999043706A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
EP1056774A1 (de)	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminal verkürzte glp-1 derivate
JP2002506792A (ja)	1998-02-27	2002-03-05	ノボノルディスクアクティーゼルスカブ	Ｎ末端修飾ｇｌｐ−１誘導体
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
JP4716641B2 (ja)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
EP1970072A1 (de)	2000-09-18	2008-09-17	Sanos Bioscience A/S	Verwendung von GLP-2-Peptiden zur Behandlung von Hyperparathyreodismus
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU3938402A (en)	2000-12-13	2002-06-24	Lilly Co Eli	Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1949908A1 (de)	2001-03-07	2008-07-30	Novo Nordisk A/S	Kombinierter Einsatz von Derivaten von GLP-1-Analoga und PPAR-Liganden
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
ATE408414T1 (de) *	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
US7020706B2 (en)	2002-06-17	2006-03-28	Bmc Software, Inc.	Method and system for automatically updating multiple servers
US20040024285A1 (en)	2002-06-21	2004-02-05	Helmut Muckter	Blood pump with impeller
ATE549028T1 (de) *	2003-05-15	2012-03-15	Tufts College	Stabile analoga von glp-1
US8318668B2 (en) *	2005-09-08	2012-11-27	Trustees Of Tufts College	Stabilized GLP-1 analogs

2004
- 2004-05-17 AT AT04752496T patent/ATE549028T1/de active
- 2004-05-17 CN CN2004800198500A patent/CN1822851B/zh not_active Expired - Fee Related
- 2004-05-17 WO PCT/US2004/015488 patent/WO2004103390A2/en not_active Ceased
- 2004-05-17 AU AU2004240630A patent/AU2004240630B2/en not_active Ceased
- 2004-05-17 CA CA2525574A patent/CA2525574C/en not_active Expired - Fee Related
- 2004-05-17 EP EP20040752496 patent/EP1633384B1/de not_active Expired - Lifetime
- 2004-05-17 CN CN2011100388475A patent/CN102174102A/zh active Pending
- 2004-05-17 ES ES04752496T patent/ES2383752T3/es not_active Expired - Lifetime
- 2004-05-17 JP JP2006533167A patent/JP4699374B2/ja not_active Expired - Fee Related
- 2004-05-17 US US10/847,220 patent/US7259234B2/en not_active Expired - Fee Related
2005
- 2005-11-09 IL IL171854A patent/IL171854A/en not_active IP Right Cessation
2007
- 2007-08-21 US US11/842,518 patent/US7994121B2/en not_active Expired - Fee Related
2011
- 2011-01-07 AU AU2011200062A patent/AU2011200062B2/en not_active Ceased
- 2011-08-09 US US13/205,844 patent/US9102756B2/en not_active Expired - Fee Related
2014
- 2014-05-08 IL IL232501A patent/IL232501A/en not_active IP Right Cessation
2015
- 2015-07-24 US US14/808,121 patent/US20170246255A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2011200062B2 (en)	2013-01-10
HK1088840A1 (en)	2006-11-17
CN1822851B (zh)	2011-04-13
AU2004240630B2 (en)	2010-10-07
ES2383752T3 (es)	2012-06-26
IL171854A (en)	2014-05-28
US20050049177A1 (en)	2005-03-03
CN1822851A (zh)	2006-08-23
US7259234B2 (en)	2007-08-21
WO2004103390A3 (en)	2005-06-30
WO2004103390A2 (en)	2004-12-02
JP2007530442A (ja)	2007-11-01
EP1633384B1 (de)	2012-03-14
US20080051557A1 (en)	2008-02-28
US20170246255A1 (en)	2017-08-31
AU2004240630A1 (en)	2004-12-02
CA2525574A1 (en)	2004-12-02
US7994121B2 (en)	2011-08-09
CA2525574C (en)	2015-06-30
US9102756B2 (en)	2015-08-11
EP1633384A2 (de)	2006-03-15
IL232501A0 (en)	2014-06-30
JP4699374B2 (ja)	2011-06-08
US20120130044A1 (en)	2012-05-24
CN102174102A (zh)	2011-09-07
IL232501A (en)	2016-11-30
AU2011200062A1 (en)	2011-01-27

Publication	Publication Date	Title
ATE549028T1 (de)	2012-03-15	Stabile analoga von glp-1
ATE509618T1 (de)	2011-06-15	Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
CY1111212T1 (el)	2015-06-11	Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
HRP20040354B1 (en)	2012-10-31	Novel cyclosporin analog microemulsion preconcentrates
CY1112267T1 (el)	2015-12-09	Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
MX2021013743A (es)	2021-12-10	Subunidad s1 modificada de la proteina de espicula de coronavirus.
MXPA03000626A (es)	2004-07-30	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
ATE486587T1 (de)	2010-11-15	Formulierungen zur oralen verabreichung von wirkstoffen
EP1641824A4 (de)	2008-02-13	Analoga von peptiden der relaxin-superfamilie
EA200970132A1 (ru)	2009-08-28	Аналоги морфолинила и пирролидинила
ATE389662T1 (de)	2008-04-15	Cardioprotektive phosphonate
BR0211761A (pt)	2007-01-09	depsipeptìdeos e processos para preparar os mesmos
MX2020013296A (es)	2021-05-27	Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
WO2005058252A3 (en)	2006-08-31	Glp-1 pharmaceutical compositions
WO2004074315A3 (en)	2004-11-25	Analogues of glp-1
MXPA03010158A (es)	2004-03-10	Sulfonamidas.
EP1401808A4 (de)	2004-08-25	Gpe-analoga und peptidomimetika
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
HRP20050024A2 (en)	2006-02-28	Pegylated t20 polypeptide
DK1079849T3 (da)	2002-04-22	Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
ATE457736T1 (de)	2010-03-15	Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
NO20063521L (no)	2006-10-26	Blandinger, fremgangsmater og anvendelser av en ny peptidfamilie
HRP20041058B1 (hr)	2013-11-22	Poboljšanje smjese sintetskih lipida za pripravke tenzida za ponovno uspostavljanje
ATE342914T1 (de)	2006-11-15	Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
NO20060675L (no)	2006-04-06	Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider